Compare AGM & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | TRVI |
|---|---|---|
| Founded | 1987 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 1995 | 2019 |
| Metric | AGM | TRVI |
|---|---|---|
| Price | $219.11 | $17.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $215.00 | $21.55 |
| AVG Volume (30 Days) | 83.1K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | 1.09 | ★ 31.91 |
| EPS | ★ 10.15 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.97 | N/A |
| Revenue Next Year | $12.21 | N/A |
| P/E Ratio | $21.65 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $136.57 | $6.93 |
| 52 Week High | $248.29 | $20.22 |
| Indicator | AGM | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 49.63 | 54.01 |
| Support Level | $166.64 | $17.49 |
| Resistance Level | $240.49 | $19.30 |
| Average True Range (ATR) | 5.46 | 0.79 |
| MACD | -2.92 | -0.05 |
| Stochastic Oscillator | 14.12 | 60.44 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, non-IPF interstitial lung disease, or non-IPF ILD, and refractory chronic cough, or RCC. Haduvio is an oral extended-release formulation of nalbuphine. The Company operates and manages its business as one reportable segment. Such a segment is the business of developing and commercializing the investigational therapy Haduvio.